JP2023501611A5 - - Google Patents
Info
- Publication number
- JP2023501611A5 JP2023501611A5 JP2022527794A JP2022527794A JP2023501611A5 JP 2023501611 A5 JP2023501611 A5 JP 2023501611A5 JP 2022527794 A JP2022527794 A JP 2022527794A JP 2022527794 A JP2022527794 A JP 2022527794A JP 2023501611 A5 JP2023501611 A5 JP 2023501611A5
- Authority
- JP
- Japan
- Prior art keywords
- human patient
- pharmaceutical composition
- dose
- cells
- genetically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934975P | 2019-11-13 | 2019-11-13 | |
| US62/934,975 | 2019-11-13 | ||
| US202063034563P | 2020-06-04 | 2020-06-04 | |
| US63/034,563 | 2020-06-04 | ||
| PCT/IB2020/060720 WO2021095011A1 (en) | 2019-11-13 | 2020-11-13 | Cd70+ solid tumor therapy using genetically engineered t cells targeting cd70 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501611A JP2023501611A (ja) | 2023-01-18 |
| JP2023501611A5 true JP2023501611A5 (enExample) | 2023-11-09 |
Family
ID=73695086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527794A Pending JP2023501611A (ja) | 2019-11-13 | 2020-11-13 | Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用するｃｄ７０＋固形腫瘍療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230355761A1 (enExample) |
| EP (1) | EP4058054A1 (enExample) |
| JP (1) | JP2023501611A (enExample) |
| KR (1) | KR20220101128A (enExample) |
| CN (1) | CN114845729A (enExample) |
| AU (1) | AU2020385062A1 (enExample) |
| BR (1) | BR112022009141A2 (enExample) |
| CA (1) | CA3158114A1 (enExample) |
| CO (1) | CO2022006014A2 (enExample) |
| IL (1) | IL292469A (enExample) |
| MX (1) | MX2022005816A (enExample) |
| WO (1) | WO2021095011A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220100913A (ko) * | 2019-11-13 | 2022-07-18 | 크리스퍼 테라퓨틱스 아게 | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법 |
| US20220378829A1 (en) * | 2021-05-12 | 2022-12-01 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating solid tumors |
| US20230114887A1 (en) | 2021-10-12 | 2023-04-13 | Lg Energy Solution, Ltd. | Battery pack and vehicle including the same |
| WO2023072307A1 (zh) * | 2021-10-25 | 2023-05-04 | 重庆精准生物技术有限公司 | 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用 |
| WO2025038646A1 (en) * | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
| WO2026136848A2 (en) * | 2024-12-20 | 2026-06-25 | Juno Therapeutics, Inc. | Cd70-targeted cars and engineered cells comprising same and related methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466291B2 (en) * | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
| EP3484455A2 (en) * | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| EP3697500A1 (en) * | 2017-10-18 | 2020-08-26 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| AU2019206724A1 (en) * | 2018-01-15 | 2020-07-16 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| KR20220100913A (ko) * | 2019-11-13 | 2022-07-18 | 크리스퍼 테라퓨틱스 아게 | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법 |
-
2020
- 2020-11-13 KR KR1020227019521A patent/KR20220101128A/ko not_active Withdrawn
- 2020-11-13 BR BR112022009141A patent/BR112022009141A2/pt not_active Application Discontinuation
- 2020-11-13 MX MX2022005816A patent/MX2022005816A/es unknown
- 2020-11-13 WO PCT/IB2020/060720 patent/WO2021095011A1/en not_active Ceased
- 2020-11-13 EP EP20817495.3A patent/EP4058054A1/en active Pending
- 2020-11-13 CN CN202080086734.XA patent/CN114845729A/zh active Pending
- 2020-11-13 CA CA3158114A patent/CA3158114A1/en active Pending
- 2020-11-13 AU AU2020385062A patent/AU2020385062A1/en not_active Abandoned
- 2020-11-13 US US17/776,871 patent/US20230355761A1/en not_active Abandoned
- 2020-11-13 IL IL292469A patent/IL292469A/en unknown
- 2020-11-13 JP JP2022527794A patent/JP2023501611A/ja active Pending
-
2022
- 2022-05-09 CO CONC2022/0006014A patent/CO2022006014A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501602A5 (enExample) | ||
| US12629430B2 (en) | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors | |
| JP6963051B2 (ja) | 免疫療法のための組成物および方法 | |
| ES3061201T3 (en) | Methods and compositions for modified t cells | |
| US20250320306A1 (en) | Methods for production of tissue resident memory-like t cells and use thereof | |
| Nie et al. | Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | |
| EP3858388B1 (en) | Chimeric antigen receptor (car) t cells as therapeutic interventions for gvhd | |
| US20240139248A1 (en) | Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19 | |
| EP3151854B1 (en) | Mesothelin-targeted chimeric antigen receptors and uses thereof | |
| Wang et al. | A novel adoptive synthetic TCR and antigen receptor (STAR) T‐cell therapy for B‐cell acute lymphoblastic leukemia | |
| KR102363191B1 (ko) | 면역치료용 조성물 및 방법 | |
| ES3032321T3 (en) | Toxicity management for anti-tumor activity of cars | |
| Fan et al. | Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors | |
| CN116874608A (zh) | 嵌合抗原受体 | |
| US20210246221A1 (en) | Chimeric antigen receptor targeting sialyl lewis a and uses thereof | |
| JP2022531185A5 (enExample) | ||
| Chen et al. | The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments | |
| US20210236554A1 (en) | Low dose radiation conditioning for immunotherapy | |
| JP2024514149A (ja) | ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用 | |
| Noubissi et al. | Mechanisms of cell fusion in cancer | |
| CN121263436A (zh) | 用于治疗病症的工程化免疫细胞，构造及其方法 | |
| CN120035446A (zh) | 表达抗cd70嵌合受体的细胞及其用途 | |
| KR102809807B1 (ko) | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 | |
| Zheng et al. | Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects | |
| US20260077046A1 (en) | Targeting the pvr axis using car t cell therapy and combinations |